This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eisenhofer, G. Articles by Pacak, K. Search for Related Content PubMed PubMed Citation Articles by Eisenhofer, G. Articles by Pacak, K.

Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes

Clinical Neurocardiology Section and Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke (G.E., T.-T.H., S.-T.L., A.V., D.S.G.); Urologic Oncology Branch, National Cancer Institute (M.M.W., W.M.L.); and Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development (S.R.B., K.P.), National Institutes of Health, Bethesda, Maryland 20892; Department of Clinical Pathophysiology, University of Florence (M.M.), Florence, Italy; and Department of Internal Medicine, St. Radboud University Hospital (J.W.M.L.), Nijmegen, The Netherlands

Address all correspondence and requests for reprints to: Dr. Graeme Eisenhofer, Building 10, Room 6N252, National Institutes of Health, 10 Center Drive, MSC 1620, Bethesda, Maryland 20892-1620. E-mail: ge{at}box-g.nih.gov

This study examined the mechanisms linking different biochemical and clinical phenotypes of pheochromocytoma in multiple endocrine neoplasia type 2 (MEN 2) and von Hippel-Lindau (VHL) syndrome to underlying differences in the expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, and of phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts norepinephrine to epinephrine. Signs and symptoms of pheochromocytoma, plasma catecholamines and metanephrines, and tumor cell neurochemistry and expression of TH and PNMT were examined in 19 MEN 2 patients and 30 VHL patients with adrenal pheochromocytomas. MEN 2 patients were more symptomatic and had a higher incidence of hypertension (mainly paroxysmal) and higher plasma concentrations of metanephrines, but paradoxically lower total plasma concentrations of catecholamines, than VHL patients. MEN 2 patients all had elevated plasma concentrations of the epinephrine metabolite, metanephrine, whereas VHL patients showed specific increases in the norepinephrine metabolite, normetanephrine. The above differences in clinical presentation were largely explained by lower total tissue contents of catecholamines and expression of TH and negligible stores of epinephrine and expression of PNMT in pheochromocytomas from VHL than from MEN 2 patients. Thus, mutation-dependent differences in the expression of genes controlling catecholamine synthesis represent molecular mechanisms linking the underlying mutation to differences in clinical presentation of pheochromocytoma in patients with MEN 2 and the VHL syndrome.

This article has been cited by other articles:

				A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF]

				K. Pacak Preoperative Management of the Pheochromocytoma Patient J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4069 - 4079. [Abstract] [Full Text] [PDF]

				A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585. [Abstract] [Full Text] [PDF]

				L. Green-Golan, C. Yates, B. Drinkard, C. VanRyzin, G. Eisenhofer, M. Weise, and D. P. Merke Patients with Classic Congenital Adrenal Hyperplasia Have Decreased Epinephrine Reserve and Defective Glycemic Control during Prolonged Moderate-Intensity Exercise J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3019 - 3024. [Abstract] [Full Text] [PDF]

				F. M Brouwers, S. Glasker, A. F Nave, A. O Vortmeyer, I. Lubensky, S. Huang, M. S Abu-Asab, G. Eisenhofer, R. J Weil, D. M Park, et al. Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B Endocr. Relat. Cancer, June 1, 2007; 14(2): 463 - 471. [Abstract] [Full Text] [PDF]

				S. R BORNSTEIN and A.-P. GIMENEZ-ROQUEPLO Genetic testing in pheochromocytoma: increasing importance for clinical decision making. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 94 - 103. [Abstract] [Full Text] [PDF]

				D. E BENN, A. L. RICHARDSON, D. J MARSH, and B. G ROBINSON Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 104 - 111. [Abstract] [Full Text] [PDF]

				T.-T. HUYNH, K. PACAK, D. L WONG, W. M. LINEHAN, D. S GOLDSTEIN, A. G ELKAHLOUN, P. J MUNSON, and G. EISENHOFER Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von hippel-lindau syndrome and multiple endocrine neoplasia type 2. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 241 - 252. [Abstract] [Full Text] [PDF]

				S. CLEARY and J. K PHILLIPS The norepinephrine transporter and pheochromocytoma. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 263 - 269. [Abstract] [Full Text] [PDF]

				A. MACHENS, M. BRAUCKHOFF, O. GIMM, and H. DRALLE Risk-Oriented Approach to Hereditary Adrenal Pheochromocytoma. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 417 - 428. [Abstract] [Full Text] [PDF]

				H. AHLMAN Malignant pheochromocytoma: state of the field with future projections. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 449 - 464. [Abstract] [Full Text] [PDF]

				C. Jimenez, G. Cote, A. Arnold, and R. F. Gagel Should Patients with Apparently Sporadic Pheochromocytomas or Paragangliomas be Screened for Hereditary Syndromes? J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2851 - 2858. [Abstract] [Full Text] [PDF]

				E. R Woodward and E. R Maher Von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr. Relat. Cancer, June 1, 2006; 13(2): 415 - 425. [Abstract] [Full Text] [PDF]

				T.-T. Huynh, K. Pacak, F. M Brouwers, M. S Abu-Asab, R. A Worrell, M. M Walther, A. G Elkahloun, D. S Goldstein, S. Cleary, and G. Eisenhofer Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 Eur. J. Endocrinol., October 1, 2005; 153(4): 551 - 563. [Abstract] [Full Text] [PDF]

				S. J. Marx and W. F. Simonds Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes Endocr. Rev., August 1, 2005; 26(5): 615 - 661. [Abstract] [Full Text] [PDF]

				M. S. Lora, S. G. Waguespack, J. F. Moley, and E. C. Walvoord Adrenal Ganglioneuromas in Children with Multiple Endocrine Neoplasia Type 2: A Report of Two Cases J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4383 - 4387. [Abstract] [Full Text] [PDF]

				T. W. A. Vogel, F. M. Brouwers, I. A. Lubensky, A. O. Vortmeyer, R. J. Weil, M. M. Walther, E. H. Oldfield, W. M. Linehan, K. Pacak, and Z. Zhuang Differential Expression of Erythropoietin and Its Receptor in von Hippel-Lindau-Associated and Multiple Endocrine Neoplasia Type 2-Associated Pheochromocytomas J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3747 - 3751. [Abstract] [Full Text] [PDF]

				G. Eisenhofer, J. W.M. Lenders, D. S. Goldstein, M. Mannelli, G. Csako, M. M. Walther, F. M. Brouwers, and K. Pacak Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines Clin. Chem., April 1, 2005; 51(4): 735 - 744. [Abstract] [Full Text] [PDF]

				W H van Houtum, E P M Corssmit, P B Douwes Dekker, J C Jansen, A G L van der Mey, A H J T Brocker-Vriends, P E M Taschner, M Losekoot, M Frolich, M P M Stokkel, et al. Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas Eur. J. Endocrinol., January 1, 2005; 152(1): 87 - 94. [Abstract] [Full Text] [PDF]

				G Eisenhofer, T-T Huynh, K Pacak, F M Brouwers, M M Walther, W M Linehan, P J Munson, M Mannelli, D S Goldstein, and A G Elkahloun Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome Endocr. Relat. Cancer, December 1, 2004; 11(4): 897 - 911. [Abstract] [Full Text] [PDF]

				G. Eisenhofer, S. R Bornstein, F. M Brouwers, N.-K. V Cheung, P. L Dahia, R. R de Krijger, T. J Giordano, L. A Greene, D. S Goldstein, H. Lehnert, et al. Malignant pheochromocytoma: current status and initiatives for future progress Endocr. Relat. Cancer, September 1, 2004; 11(3): 423 - 436. [Abstract] [Full Text] [PDF]

				G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management Endocr. Rev., April 1, 2004; 25(2): 309 - 340. [Abstract] [Full Text] [PDF]

				J. Bryant, J. Farmer, L. J. Kessler, R. R. Townsend, and K. L. Nathanson Pheochromocytoma: The Expanding Genetic Differential Diagnosis J Natl Cancer Inst, August 20, 2003; 95(16): 1196 - 1204. [Abstract] [Full Text] [PDF]

				D. S. Goldstein, G. Eisenhofer, and I. J. Kopin Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 800 - 811. [Abstract] [Full Text] [PDF]

				W. G. Meijer, S. C.V.M. Copray, H. Hollema, I. P. Kema, N. Zwart, I. Mantingh-Otter, T. P. Links, P. H.B. Willemse, and E. G.E. de Vries Catecholamine-Synthesizing Enzymes in Carcinoid Tumors and Pheochromocytomas Clin. Chem., April 1, 2003; 49(4): 586 - 593. [Abstract] [Full Text] [PDF]

				A. V. Kuznetsova, J. Meller, P. O. Schnell, J. A. Nash, M. L. Ignacak, Y. Sanchez, J. W. Conaway, R. C. Conaway, and M. F. Czyzyk-Krzeska von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination PNAS, March 4, 2003; 100(5): 2706 - 2711. [Abstract] [Full Text] [PDF]

				C. A. Koch, K. Pacak, and G. P. Chrousos The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5367 - 5384. [Abstract] [Full Text] [PDF]

				R. J. PARMER and O. ZINDER Catecholaminergic Pathways, Chromaffin Cells, and Human Disease Ann. N.Y. Acad. Sci., October 1, 2002; 971(1): 497 - 505. [Abstract] [Full Text] [PDF]

				M. Weise, D. P. Merke, K. Pacak, M. M. Walther, and G. Eisenhofer Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1955 - 1960. [Abstract] [Full Text] [PDF]

				A. L. Bauer, W. R. Paulding, J. B. Striet, P. O. Schnell, and M. F. Czyzyk-Krzeska Endogenous von Hippel-Lindau Tumor Suppressor Protein Regulates Catecholaminergic Phenotype in PC12 Cells Cancer Res., March 1, 2002; 62(6): 1682 - 1687. [Abstract] [Full Text] [PDF]

				S. J. Marx and L. K. Nieman Aggressive Pituitary Tumors in MEN1: Do They Refute the Two-Hit Model of Tumorigenesis? J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 453 - 456. [Full Text] [PDF]